Drugs.com - New Drug Approvals

FDA Approves Zevaskyn (prademagene zamikeracel) Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa

CLEVELAND, April 29, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the U.S. Food and Drug Administration (FDA) has approved Zevaskyn (pronounced as ‘ZEE-vah-skin’) (prademagene zamikeracel)...

May 12, 2025 - 10:14
 0
FDA Approves Zevaskyn (prademagene zamikeracel) Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa
CLEVELAND, April 29, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the U.S. Food and Drug Administration (FDA) has approved Zevaskyn (pronounced as ‘ZEE-vah-skin’) (prademagene zamikeracel)...
Read More

Tags:

Previous Article

Rinvoq (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)

Next Article

FDA Approves Penpulimab-kcqx for the Treatment of Advanced Nasopharyngeal Carcinoma

Related Posts

Argenx Announces FDA Approval of Vyvgart Hytrulo Prefil...

May 12, 2025  0

FDA Grants Accelerated Approval to Avmapki Fakzynja Co-Pack (avutometinib capsules/defactinib tablets) for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

FDA Grants Accelerated Approval to Avmapki Fakzynja Co-...

May 13, 2025  0

FDA Approves Keytruda (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy

FDA Approves Keytruda (pembrolizumab) for PD-L1+ Resect...

Jun 14, 2025  0